Streetbeat News

Price Targets

ACN

BMO Capital analyst Keith Bachman maintains a Market Perform rating on Accenture (NYSE:ACN) and raises the price target from $327 to $365.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:40 pm

HPE

Credit Suisse analyst Shannon Cross maintains an Outperform rating on Hewlett Packard (NYSE:HPE) and raises the price target from $18 to $21.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:38 pm

SLRN

Morgan Stanley analyst Vikram Purohit reiterated an Overweight rating on Acelyrin (NASDAQ:SLRN) and maintained a $29 price target.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 12:37 pm

SKIN

The Beauty Health Company's shares are trading lower after Stifel downgraded the stock from Buy to Hold and lowered its price target from $17 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 12:33 pm

AKBA

HC Wainwright & Co. analyst Ed Arce reiterates a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintains a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:29 pm

KDNY

HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Chinook Therapeutics (NASDAQ:KDNY) and maintained a $40 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:28 pm

OCEA

Ocean Biomedical's share price target has been increased to $17.63 by Fundamental Research Corp. (FRC) following positive results from an independent study on glioblastoma tumor suppression, new patents, and recent financing. FRC's report highlights Ocean Biomedical's diversified development pipeline, which includes drug candidates for oncology, fibrosis, and infectious diseases.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:20 pm

URGN

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on UroGen Pharma (NASDAQ:URGN) and maintained a $23 price target.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:06 pm

SMTC

Craig-Hallum analyst Anthony Stoss initiates coverage on Semtech (NASDAQ:SMTC) with a Buy rating and announces a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

June 21, 2023 | 12:05 pm